AstraZeneca (AZN)
Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
About AstraZeneca
Copy link to sectionWhat is AstraZeneca?
Copy link to sectionAstraZeneca is a British pharmaceutical company. Headquartered in Cambridge, United Kingdom, and founded in 1999, it now operates in over 100 countries worldwide. It focuses on developing innovative treatments for various diseases, including oncology, cardiovascular, renal, metabolism, respiratory, and immunology.
How does AstraZeneca make money?
Copy link to sectionAstraZeneca makes money by selling pharmaceutical products, collaborations and partnerships, as well as licensing and royalty agreements. It has several treatments and therapies and became a household name during the pandemic when it was one of the first companies to release a coronavirus vaccine.
What is AstraZeneca’s best selling product?
Copy link to sectionAstraZeneca’s best selling products are from its oncology department. Tagrisso, which is used to treat non-small cell lung cancer, was its best selling drug in 2022, with sales of $5.4 billion. Another cancer drug, Imfinzi, generated $4.4 billion for the same period. In 2022, AstraZeneca reported total revenue of $29.2 billion, up 6% from the previous year.
Who are the key executives at AstraZeneca?
Copy link to sectionPascal Soriot is the current CEO of AstraZeneca, here are a few other members of its leadership team.
- Pascal Soriot D.V.M., M.B.A. CEO & Exec. Director
- Aradhana Sarin M.D. Exec. Director
- Pam P. Cheng. EVP of Operations, IT & Sustainability and Member of External Sustainability Advisory Board
- Andrew P. Barnett. Head of Investor Relations
- Jeffrey Pott. CHRO, Chief Compliance Officer, Gen. Counsel & Member of External Sustainability Advisory Board
- Gonzalo Vina. Head of Global Media Relations
- Menelas Pangalos Ph.D. EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board
- Ruud Dobber Ph.D. Exec. Vice-Pres of BioPharmaceuticals Bus. Unit
- Susan Mary Galbraith. M.D., Ph.D. Exec. VP of Oncology R&D
- Leon Wang. Exec. VP of International & China Pres
Where can I buy shares in AstraZeneca?
Copy link to sectionYou can buy AstraZeneca stock on a stock trading platform. These platforms are extremely simple to use but there are different options to suit your specific needs. If you are a first-time investor you might want to use a trading platform for beginners, while if you plan on doing a lot of trading from your phone, a stock trading app might be best.
Are there any other ways to invest in AstraZeneca?
Copy link to sectionThe simplest way to invest in AstraZeneca is to buy shares through a stock broker. However, you can also invest through an ETF or a fund. The best ETFs allow you to invest in the stock market more generally rather than focus on one company.
AstraZeneca is part of the Nasdaq index, so you can invest in an ETF that tracks that index, or choose a pharmaceutical ETF that lets you own a basket of related stocks from the same industry.
More about the AZN price
Copy link to sectionWhat is the AstraZeneca stock price today?
Copy link to sectionThe AZN stock price today is currently $68.60 as of 29 March 2023. The price of AstraZeneca is up 5.4% over the past 52 weeks. You can use the live AstraZeneca stock chart to track the NASDAQ:AZN price in real time above, or compare the AstraZeneca value today to its past performance using the AstraZeneca financials tab at the top of this page.
What is the 52-week low for AstraZeneca stock?
Copy link to sectionThe 52-week low for AstraZeneca stock is $52.65. AZN stock is currently 30.11% above the 52-week low.
What is the 52-week high for AstraZeneca stock?
Copy link to sectionThe 52-week high for AstraZeneca stock is $72.12. AZN stock is currently 4.35%] below the 52-week high.
What is the stock forecast for AstraZeneca?
Copy link to sectionThe average AstraZeneca stock forecast has a price target of $78.87 by the end of 2023. AstraZeneca’s latest financial results, the broader economic outlook, and the amount of competition in the industry all influence these forecasts.
It’s best to take analyst forecasts with a grain of salt but you can use their estimates to help you understand the weight of opinion about a stock.
More stock guides
Copy link to sectionFAQs
Copy link to sectionInvezz is a place where people can find reliable, unbiased information about finance, trading, and investing – but we do not offer financial advice and users should always carry out their own research. The assets covered on this website, including stocks, cryptocurrencies, and commodities can be highly volatile and new investors often lose money. Success in the financial markets is not guaranteed, and users should never invest more than they can afford to lose. You should consider your own personal circumstances and take the time to explore all your options before making any investment. Read our risk disclaimer >